• Lexaria, a global innovator in drug delivery platforms, is exploring alternatives to traditional diabetes and obesity management through its patented DehydraTECH(TM) technology to potentially enhance oral ingestion vs. injection treatment of GLP-1 drugs
• The company has made significant strides pairing their bioavailability enhancing DehydraTECH with glucagon-like peptide-1 (“GLP-1”) drugs used for treatment of diabetes and obesity
• Projections are that by 2030 over 54.9 of Americans could have diabetes, and that by 2045 one in eight adults globally will be living with the condition

According to the International Diabetes Federation Diabetes Atlas of 2021, 10.5% of adults aged between 20 and 79 globally have diabetes. In addition, almost half of them are unaware that they are living with the condition. The Federation further projects that by 2045, one in eight adults in the world will be living with diabetes. This will represent approximately 783 million people, an increase of 46% from the current numbers (https://cnw.fm/QsqcW).

The figures in the United States are just as startling, with 38.4 million people of all ages, or 11.6% of the country’s population having diabetes, according to the Centers for Disease Control (“CDC”) (https://cnw.fm/dHQHL). Also, a Population Health Management report shows estimates that, by…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

This press release is distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lexaria Bioscience (NASDAQ: LEXX) Exploring Alternative Diabetes and Obesity Treatments.